Alnylam Pharma (ALNY) Tops Q3 EPS by 8c
Get Alerts ALNY Hot Sheet
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.58), $0.08 better than the analyst estimate of ($1.66). Revenue for the quarter came in at $125.9 million versus the consensus estimate of $120.75 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- Youdao, Inc. (DAO) Tops Q2 EPS by 50c
- Deere shares climb as fiscal Q3 earnings and revenue top estimates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share